05.01.2016

Unfortunately, however, only very little is being invested here.

Why is this the case?
A major proportion of the people affected or threatened by poverty-related and neglected diseases – PRNDs for short – are among the poorer groups in society in low- and middle-income countries, which means they do not have much purchasing power. Therefore, conventional pharmaceutical industry has relatively little interest in developing new drugs, vaccines or diagnostics for this target group. This market failure is also referred to as the 10:90 gap: only ten per cent of global health research is devoted to the diseases of poverty, which account for 90 per cent of the global disease burden.

But at least the topic of health has once again attracted more political attention this year; the G7 Conference comes to mind here. Does that make you optimistic?
Global health has generally gained more weight in the development and research agenda over the last ten to fifteen years.